Men who have sex with men (MSM) living with HIV are at high risk for anal high-grade squamous intraepithelial lesions (HSILs) and cancer. The best management of anal HSIL remains unclear. Our objective was to assess whether argon plasma coagulation (APC) could be safe, well tolerated and efficient to treat anal HSILs in MSM living with HIV.
Introduction
Men who have sex with men (MSM) living with HIV are the group at highest risk for anal cancer [1] [2] [3] [4] [5] [6] , because of their high prevalence of anal high-risk human papillomavirus (HR-HPV) infection [6, 7] . Although the benefit of anal cancer screening remains unproven, many experts recommend screening for and treatment of high-grade squamous intraepithelial lesions (HSILs) to prevent progression to invasive anal cancer [8] [9] [10] . This strategy was indeed demonstrated to be successful to prevent cervical cancer, another HPV-related cancer with many similarities to anal cancer [11] [12] [13] . Until we learn from ongoing randomized clinical trials assessing the benefit of anal HSIL treatment to prevent anal cancer, the largest one being the Anal Cancer HSIL Outcomes Research (ANCHOR) trial (clinicaltrials.gov: NCT02135419), many clinicians treat HSILs preventively.
The best treatment modality for anal HSILs remains undetermined [14] . Surgical excision carries a high risk of long-term consequences such as nonhealing wounds, anal stenosis or incontinence [15, 16] . Less invasive treatment options such as imiquimod, cidofovir, fluorouracil, laser ablation, infrared coagulation (IRC) and electrocautery are other options, but their reported efficacy remains modest, with important side effects and high recurrence rates, especially in HIV-positive populations.
Argon plasma coagulation (APC) is a noncontact electrosurgical technique used by endoscopists to treat numerous pathologies of the gastrointestinal mucosa [17] . The argon gas is ionized through a high-frequency electrical current and becomes electrically conductive, and this is called the argon plasma [18] . The argon plasma transmits the current to the target tissue and creates a zone of coagulation of approximately 2-3 mm depth. APC has never been studied for anal HSIL treatment and is not labelled for this use. The objective of this pilot study was to assess whether APC could be safe, well tolerated and efficient to treat anal HSILs in MSM living with HIV. A secondary objective was to assess the impact of HSIL treatment on HPV typing and viral loads.
Methods

Study design
We conducted a prospective, open-label, pilot study to evaluate the tolerability, safety, and efficacy of APC to treat anal HSILs in HIV-positive MSM. Participants were recruited from two high-resolution anoscopy (HRA) clinics of Montreal (Centre Hospitalier de l'Universit e de Montr eal and McGill University Health Center) and from the Human Immunodeficiency and Papilloma Virus Research Group (HIPVIRG) cohort study between February 2007 and February 2008. The study was funded by the Canadian Institutes of Health Research (CIHR) Canadian HIV Trials Network, and the AIDS Network of Fonds de Recherche du Qu ebec en Sant e (FRQS) and registered through clinicaltrials.gov (NCT00428285). It was approved by the community advisory committee of the CIHR Canadian HIV Trials Network and the research ethics boards of the two hospitals. All study participants provided written informed consent.
Men identifying as MSM, aged 18-65 years, living with HIV for at least 6 months, and diagnosed with persistent anal HSILs, as confirmed histologically by two biopsies at least 4 months apart in the previous year, were eligible to participate in the study. Participants were excluded if they had a past history of invasive anal cancer, had received chemotherapy or radiotherapy for anal HSILs or cancer, harboured circumferential HSILs, were currently receiving interferon or cidofovir, or had an international normalized ratio ≥ 1.5 or an absolute platelet count < 50 000 platelets/lL.
Study conduct
A persistent histological anal HSIL was first identified, and its location and size determined, through HRA with biopsies within 5 weeks prior to the first APC treatment visit (T0). Follow-up visits were scheduled at 3, 6, 12, 18 and 24 months after T0, and included a perianal visual examination, a digital ano-rectal examination and an HRA. If the HSIL persisted or recurred after the first APC treatment, additional treatments were offered up to a maximum of four, at least 1 month apart. All HRA visits and APC treatments were performed by Dr G. Ghattas until the end of APC treatments. Follow-up visits were shared between Dr Ghattas and author FC.
APC treatment
Local anaesthesia with xylocaine 2% injections preceded APC treatments for all participants. Treatments were performed under HRA through a clear plastic anoscope to properly visualize and identify the targeted area. Treatment proceeded by continuous application of energy with the argon plasma coagulator (System 7500, ConMed, Utica, New York, USA) with settings of 40 W, gas flow of 1.5 L/min, and a standard 5 Fr catheter with the opening at the tip, to achieve a depth of 2-3 mm. Necrotic tissue was then removed with forceps until the basement membrane was visualized.
Data collected
Pain, bleeding and other symptoms were assessed through questionnaires immediately after the procedure, by phone at 24 h and 1 week following each treatment, and in person semi-annually for 2 years. Anal cells for HPV testing were collected at baseline, 12 and 24 months with a saline-moistened polyester tipped swab inserted 3 cm into the anal canal and then removed with a twirling motion.
The swab was then agitated in 1.5 mL of PreservCyt solution (Cytyc Corporation, Marlborough, Massachusetts, USA). HRAs were performed 3 months after each treatment, and at 6, 12, 18 and 24 months following T0. During HRA, biopsies of visually suspicious areas of the anal canal or of previously treated areas and the transformation zone were obtained for histological assessment through the regular pathology services of the respective hospitals.
HPV genotyping and viral loads
After centrifugation of the cell suspension in PreservCyt at 13 000 g for 15 min at 22°C, the supernatant was discarded, and the cell pellet was left to dry and resuspended in 300 uL of 20 mmol/L Tris buffer (pH 8.3). DNA was purified using a Master-Pure Kit (Epicentre, Madison, Wisconsin, USA) [19] and then tested in the Linear Array HPV genotyping assay (LA-HPV; Roche Molecular Systems, Pleasanton, California, USA) to detect 36 HPV genotypes. b-globin DNA was co-amplified to assess DNA integrity and the absence of inhibitors [20] . Samples positive for HPV-16 or HPV-18 were further tested to assess HPV viral loads with real-time polymerase chain reaction (PCR) assays as described previously [21] .
Statistical analysis
Results were recorded by double entry. Descriptive analyses were performed for efficacy and side effects. Successful clearance of lesions was considered to have occurred when the follow-up histological examination of biopsies indicated normal histology or low-grade squamous intraepithelial lesions (LSILs). Time to recurrence of HSIL after each treatment was presented through KaplanÀMeier curves. The primary outcome to assess efficacy was the absence of HSILs at the 24-month visit. As recurrences were common, and the risk of a false negative elevated with HRA identification of anal HSILs, we also used a more conservative definition of clearance, i.e. remaining free of HSILs for the complete second year of follow-up (i.e. at the 12-, 18-and 24-month visits). Statistical analyses were performed with STATA software, version 11.2 (StataCorp LLC, College Station, Texas, USA).
Results
Twenty MSM living with HIV with persistent anal HSILs entered the study and all of them completed the 24-month study follow-up. None of the participants had previously received treatment for anal HSILs. Table 1 describes the main characteristics of the participants at study entry. The median age was 49 years, 85% had an undetectable HIV viral load and 60% had 25% or less of the anal canal surface affected by anal HSILs. The median number of prevalent HR-HPV types was 3 (range [1] [2] [3] [4] [5] [6] .
While all participants received a first APC treatment at T0, the complete first treatment was performed over two separate appointments for one participant because of pain and the size of the lesion (50À75% of the anal canal). Figure 1 presents the flow chart of study participants' results and treatments received. Additional APC treatments were offered to 16 participants: seven received a total of two APC treatments, seven received three and two received four. A total of 47 APC treatments were performed throughout the study.
APC treatment efficacy
Of the 20 participants, only one never responded to APC treatments during the study, despite receiving three APC treatments. Regarding initial response, 45% (nine of 20) HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion.
had regressed to normal histology or LSIL at their first follow-up after the first APC treatment, 44% (seven of 16) after their second treatment and 67% (six of nine) after their third treatment. However, recurrences of HSILs were very commonly detected during the study, which were mostly lesion recurrences at the treated site, but eight new lesions were identified in six participants during the study, after their first APC treatment. At 2 years, 65% (13 of 20) were clear of HSILs. This included two participants for whom the histology 3 months after their second APC treatment suggested an HSIL, but their lesion at follow-up visits behaved more like an LSIL and histology of biopsies could no longer identify an HSIL. The median time to detection of recurrence was 4 months (range 1.4-10.7 months). For simplicity, the term recurrence is used here, but we recognize the possibility that these could also represent persistence with a missed HSIL at the previous visit. The 'recurrent' HSIL after the first APC treatment was in the same previously treated area for four participants, but was considered a new lesion for two. 2 The 'persistent' HSIL after the first APC treatment was in the same previously treated area for all participants, and two also had a new lesion. 3 Not all participants with HSIL recurrences received additional treatment because some of those were identified late in the study. 4 The 'recurrent' HSIL after the second APC treatment was in the same previously treated area for three participants, but was considered a new lesion for one. 5 The 'persistent' HSIL after the second APC treatment was in the same previously treated area for all seven participants, but two of them ended the study free of HSILs without further treatment. 6 The 'recurrent' HSIL after the third APC treatment was in the same previously treated area for two participants, but was considered a new lesion for one. 7 The 'persistent' HSIL after the third APC treatment was in the same previously treated area for all three participants and two also had new lesions.
No specific baseline characteristic showed a significant association with better response to treatment (verified for HPV-16 prevalence, HPV-16 or 18 viral load, number of high-risk HPV types, smoking, baseline CD4 count, and nadir CD4 count). The type-specific HPV point prevalences for HR-HPV, HPV-6 and HPV-11 at baseline, 12 and 24 months are presented in Fig. 3 . For all HPV types presented, the point prevalence either stayed unchanged or decreased during the study. Of nine participants with prevalent HPV-16 at baseline, three were clear of HPV-16 at the 24-month visit, all of them also being free of HSILs. For the others, the viral load of HPV-16 varied, but did not show a significant tendency to decrease. We also did not see a significant trend for HPV-18 viral load following treatment. All of the six participants with prevalent HPV-51 and 5 of the 10 with prevalent HPV-58 were clear of these HPV types at 24 months. Only three participants acquired new HR-HPV types during the study, while 17 had either an unchanged or a decreased number of HR-HPV types. None of the participants developed invasive anal cancer during the study period. Eighteen participants continued follow-up in another longitudinal HSIL study led by our team. This longer follow-up allowed us to determine that, of the 13 men free of HSILs at the end of the argon study, at least five had a recurrence of HSILs in the following years.
APC treatment tolerance and side effects: pain
The main side effect of APC was pain during the procedure and within 1 week post-treatment, only when passing stools in many cases. Figure 4 presents the pain level graded on a scale of 0À10 at the different study timepoints. Despite local anaesthesia with 2% xylocaine injections prior to APC (median of 4 mL injected per treatment; range 1-15 mL), participants reported a median pain grade of 6 (range 0À10) during the procedure, lasting a few seconds only, which disappeared completely immediately after the procedure for all participants. When pain was reassessed at 24 h and 1 week post treatment, 65-70% of participants reported some degree of pain. A combination of acetaminophen and codeine per os was used within the first week to relieve the pain after 55% (26 of 47) of treatments, with a median of six tablets used overall (range 1-40), and this was deemed insufficient to relieve the pain for only one participant who used a total of five doses. In long-term follow-up, all participants denied anal pain at 6 months, and three participants reported intermittent anal pain at 12 or 18 months, but this was attributed to anal fissures or a previous condition for two of them, and was reported only once without further details for the other participant.
APC treatment tolerance and side effects: bleeding and other Minimal blood loss was described by the physician performing the procedure, with an estimated median of Two patients reported fatigue impacting daily activities the day following treatment. Another participant, already known to have chronic intermittent anal pain at baseline, reported fatigue, anal pain and lower back pain keeping him at home for 2 weeks after each of his two treatments. One participant developed an ulcer and tenesmus after his second treatment, with spontaneous resolution after 1 month, and three had anal or perianal herpes recurrence. One participant reported pain post anal intercourse 3 weeks after his second treatment. No participants had anal incontinence developing after APC treatments. No signs or symptoms of infections developed after any of the treatments administered during the study.
All other minor adverse events reported after T0 were considered unrelated to the APC: shingles (two participants), anxiety (two participants), superficial thrombophlebitis, headache, vomiting for 2 days, bronchitis, dental abscess, left epididymitis, occasional urinary incontinence, giardiasis, groin fungal cutaneous infection, and gout. All serious adverse events reported in four participants were considered unrelated to APC but serious because requiring hospitalization: pyelonephritis postpyelography, decompensated nephrotic syndrome with leg oedema, dorsolumbar sprain and contusion followed by left leg deep vein thrombosis, and leg fracture requiring surgery from a bike accident.
Discussion
This is the first study on the use of APC to treat anal HSILs. Although 95% (19 of 20) of participants had their HSIL regress to normal histology or LSIL at least once during the study, the initial success after a first APC treatment was 45%, 65% of participants ended the study free of HSILs, and 35% remained free of HSILs for at least 12 months. HSIL recurrences or persistence occurred after the first APC in 85%. The variability in study designs of anal HSIL treatment limits comparison between studies. In studies of topical HSIL treatment in men living with HIV, the initial efficacy was reported to be 21-42% for intra-anal imiquimod [22, 23] , 63% for topical cidofovir 1% [24] , 21-59% for topical 5-fluorouracil [23, 25] , and 44% for photodynamic therapy [26] . With photodynamic therapy, only 16% had a sustained response ranging from 6 to 15 months [26] , and all these studies also involved < 35 participants. When analysed by lesion, in 72 men, topical 80% trichloroacetic acid showed 49% and 28% efficacy after a first and second treatment, respectively [27] . Ablative methods such as IRC and electrocautery are the most similar treatments to APC. The initial short-term efficacy in men living with HIV was reported as 39-64% for IRC [28, 29] , and 53-66% for electrocautery [23, 30] . By lesion, electrocautery was reported to lead to an initial success rate of 75% in 132 HIV-positive men, HSILs recurred in 61% of participants, and 69% were free of HSILs at their last visit [31] . We therefore conclude that APC shows a similar efficacy to other anal HSIL treatment modalities according to the reported data. However, sufficiently powered comparative trials will be required to draw precise conclusions.
Regarding side effects, the pain reported in our study was considerable during the procedure and within the first week post-treatment. This raises the need to further improve analgesia during and after treatment. We did not observe long-term complications from APC in our participants. Comparison is again challenging, as retrospective studies do not capture the description of pain as precisely as with prospective designs. When comparing our results to those of other prospective studies, all treatment modalities showed important side effects: 85% reported side effects with 5-fluorouracil [25] , 81% with 1% cidofovir [24] , and 76% with photodynamic therapy [26] . Pain was never assessed during the procedure for other ablative techniques. After electrocautery, 42% reported mild to moderate pain for up to 5 days [30] , 60% reported pain at 4 weeks [23] , 16-69% reported bleeding [23, 30] , and 2.5% developed local infection related to the procedure [30] . After IRC, mild to moderate anal pain at 4 weeks was reported in 56% of 18 participants, 67% had anal bleeding and 11% reported temporary faecal incontinence [32] . We conclude that all anal HSIL treatment modalities cause an important number of short-term side effects, mostly pain and anal bleeding, especially in the first month after treatment, but chronic or serious adverse events are rare. Local analgesia during the procedure, mild oral analgesics and stool softeners must be prescribed to all patients receiving ablative treatment of anal HSILs, and close follow-up or facilitation of medical care accessibility is important.
An important drawback of APC is the cost of equipment and installations. A new argon system currently costs around 50 000 CAN$, including the cautery device and the cart, and the disposable probes cost 200 CAN$ each (quotes obtained from ConMed, applicable to acquiring new equipment in 2017). The argon gas costs around 90 CAN$ per 17-L bottle. APC thus remains a treatment option to be considered mostly by physicians who already have APC training and access to equipment at their hospital.
The high burden of prevalent high-risk HPV infection detected in the anal canal of our participants is Of those reporting pain at 1 week, it was only when passing stools for the participant reporting grade 7, two men reporting grade 3, and three reporting grade 1À2.
e The participant reporting grade 6 pain at 12 months had pain attributable to anal fissures. The participant reporting pain at 18 months was known to have intermittent anal pain at baseline. APC, argon plasma coagulation.
concordant with previous studies [7] and explains the high rate of HSIL recurrences seen in MSM living with HIV. There is no treatment available to eradicate HPV infection. The quadrivalent prophylactic HPV vaccine showed 26% efficacy to prevent squamous intraepithelial lesions in young HIV-negative MSM [33] and a 50% lower HSIL recurrence rate also among HIV-negative MSM [34] , but there are no such data in MSM living with HIV.
The most important strengths of this study are the prospective design with 2-year follow-up, and the thorough systematic assessment of side effects at multiple time-points, including during the procedure. The pilot study design limited the precision of our estimates, the generalizability of our results, and the possibility of identifying correlates of treatment response, but was chosen to ensure the safety of participants as this was the first study of APC to treat anal HSILs. Another limitation is the potential misdiagnosis of HSILs, either by missing lesions at HRA, or by misclassifying the grade of lesions on histological examination. However, multiple semiannual follow-up HRAs were performed to ensure higher detection of HSILs.
In conclusion, our pilot study showed that APC is comparable to other anal HSIL treatment modalities reported to date in terms of efficacy and safety in MSM living with HIV. Pain is the main side effect, which requires appropriate attention and analgesia to be given to the patient during the procedure and in the following week. Cost is the main disadvantage of APC. As with all other treatment modalities for HSILs, efficacy can be improved by repeated treatments, but recurrence rates remain high. Larger and longer randomized studies will be required to better compare treatment modalities. Unfortunately, treating anal HSILs will remain a challenge until successful treatment of HPV infection or elimination of the transitional zone can be achieved.
